TORONTO, CANADA--(Marketwired - July 6, 2016) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company developing first-in-class peptide-based cancer therapeutics, is pleased to announce the members of its newly formed Clinical Advisory Board ("CAB"). The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will provide Soricimed with ongoing expert strategic guidance on the continued clinical development of its lead anti-cancer drug candidate, SOR-C13, and its preclinical oncology pipeline.
The members of Soricimed's CAB are:
--Robert L. Coleman, M.D., FACOG, FACS, MD Anderson Cancer Center, key opinion leader in cancers of the female genital tract, including Ovarian Cancer
--Siqing Fu, M.D., Ph.D., MD Anderson Cancer Center, Principle Investigator, SOR-C13 Phase I
--Manuel Hidalgo, M.D., Ph.D., BIDMC (Beth Israel Deaconess Medical Centre) & Harvard Medical School. Clinical Director of BIDMC Cancer Centre & Chief of Hematology-Oncology. A world leader in the testing and development of new agents for pancreatic and other solid tumor cancers
--Natacha Prevarskaya, Professor, USTL (Université des Sciences et Technologies de Lille). Expert in calcium ion channels, including TRPV6.
--Stephen Welch, M.D., Medical Oncologist, London Health Sciences Centre, Principle Investigator, SOR-C13 Phase I
"We are honored to have these key opinion leaders join our Clinical Advisory Board," stated Paul Gunn, President & CEO, Soricimed Biopharma, Inc. "Together, they bring a wealth of experience and expertise in our targeted cancer areas, such as pancreatic and ovarian cancer, as well as in clinical trial design and drug development. We look forward to their input as we take the next step in the clinical development of our anti-cancer peptide, SOR-C13."
"It has been exciting to be a part of Soricimed's phase 1 trial of its lead anti-cancer drug candidate, SOR-C13," commented Dr. Siqing Fu, M.D., Ph.D., MD Anderson Cancer Center & Principal Investigator, SOR C-13 Phase 1 trial. "The findings are encouraging and I look forward to working with their impressive team to conduct further study."
In February, Soricimed announced positive results of their Phase 1 multi-center, open-label, dose escalation study of first-in-class peptide SOR-C13 in subjects with advanced solid tumor cancers. SOR-C13 was found to be safe and well tolerated by subjects with advanced carcinomas commonly known to express the TRPV6 channel (such as pancreatic and ovarian cancer) and who had failed all previous anti-cancer treatments. Additionally, SOR-C13 demonstrated potential activity with 54% of subjects achieving stable disease as defined by the clinical protocol while on treatment.
About SOR-C13: SOR-C13 is a first-in-class peptide in development for the treatment of cancer. SOR-C13 binds with high selectivity and affinity to TRPV6, a calcium channel that is highly elevated in prostate, breast, lung and ovarian cancer and is correlated with poor outcomes. TRPV6-mediated Ca2+ entry is responsible for maintaining a high tumour proliferation rate, as well as increasing tumour cell survival and fortifying mechanisms that withstand cell destruction. By binding to this channel, SOR-C13 starves cancer cells of calcium that is needed for cell growth and division. Due to the high specificity of SOR-C13 for its target and its unique mechanism of action this drug candidate has resulted in fewer and less severe side effects compared to standard cancer chemotherapy. SOR-C13 is the first drug candidate targeting TRPV6 to have entered clinical development anywhere in the world.
At the recent American Association of Cancer Researchers annual meeting, Soricimed released positive results indicating safety, tolerability and potential activity in a Phase I trial of SOR-C13 in subjects with advanced solid tumour cancers. Subjects were enrolled at Juravinski Cancer Centre, London Health Sciences Centre and the University of Texas MD Anderson Cancer Center. The FDA granted SOR-C13 orphan drug status for the treatment of ovarian cancers.
About Soricimed Biopharma: Soricimed Biopharma Inc. is a private Canadian clinical-stage company developing novel cancer therapeutics and diagnostics. Using focused, innovative strategies in collaboration with major world-class cancer research institutions, Soricimed's drug candidates have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Soricimed recently announced positive results indicating safety, tolerability and potential activity in a Phase I trial of SOR-C13 in subjects with advanced solid tumour cancers. Additionally, Soricimed obtained orphan drug status for the treatment of ovarian cancers with SOR-C13. Privately held, Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com.
Partner, Hageman Communications